PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9879991-0	1998	Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.	Cysteine	87-96	ret proto-oncogene	Homo sapiens	19-22	
9879991-2	1998	Germline mutations affecting one of five cysteines (Cys609, 611, 618, 620 and 634) located in the juxtamembrane domain of the RET receptor are responsible for the vast majority of two cancer-prone disorders, multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC).	Cysteine	41-50	ret proto-oncogene	Homo sapiens	126-129	
9879991-2	1998	Germline mutations affecting one of five cysteines (Cys609, 611, 618, 620 and 634) located in the juxtamembrane domain of the RET receptor are responsible for the vast majority of two cancer-prone disorders, multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC).	Cysteine	41-50	ret proto-oncogene	Homo sapiens	208-244	
9879991-2	1998	Germline mutations affecting one of five cysteines (Cys609, 611, 618, 620 and 634) located in the juxtamembrane domain of the RET receptor are responsible for the vast majority of two cancer-prone disorders, multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC).	Cysteine	41-50	ret proto-oncogene	Homo sapiens	246-252	
9879991-10	1998	These findings provide a molecular basis explaining the range of phenotype engendered by alterations of RET cysteines and suggest a novel mechanism whereby mutations of cysteines 609, 618 and 620 exert both activating and inactivating effects.	Cysteine	108-117	ret proto-oncogene	Homo sapiens	104-107	
9879991-10	1998	These findings provide a molecular basis explaining the range of phenotype engendered by alterations of RET cysteines and suggest a novel mechanism whereby mutations of cysteines 609, 618 and 620 exert both activating and inactivating effects.	Cysteine	169-178	ret proto-oncogene	Homo sapiens	104-107